Background: One of the shortcomings of the available treatments for major depressive disorder (MDD) is the time delay between starting the treatment and achieving an antidepressant response. Objectives: We aimed to determine the effect of Ketamine as a synergistic antidepressant and anesthetic agent on MDD in electroconvulsive therapy (ECT). Patients and Methods: Twenty-two patients with MDD received Ketamine and Propofol as anesthetic agents compared with 20 patients as the control group who received Propofol in a double-blind randomized clinical trial. The Hamilton rating scale for depression was used to determine the changes in symptoms severity during ECT and a 2-week follow-up. Results: Both groups showed a reduction in depression severity, but there was no significant difference between the groups in the recovery process (P = 0.92). However, the cognitive performance recovery time in the Ketamine group was lower than that in the control group (P = 0.042). Conclusions: This study could not show the effect of Ketamine on depression recovery in a 2-week follow-up period. Nevertheless, Ketamine may provide a better cognitive performance in patients under ECT.
CITATION STYLE
Alizadeh, N. S., Maroufi, A., Nasseri, K., Najafabadi, S. H. S., Taghiabad, A. M., Gharibi, F., & Esfandiari, G. R. (2015). Antidepressant effect of combined ketamine and electroconvulsive therapy on patients with major depressive disorder: A randomized trial. Iranian Journal of Psychiatry and Behavioral Sciences, 9(3). https://doi.org/10.17795/ijpbs-1578
Mendeley helps you to discover research relevant for your work.